trial

Add-on Simvastatin in Schizophrenia Trial

NCTId NCT00605995
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 15 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2011-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
15 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-02
Primary completion
2011-08
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Simvastatin

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Stanley Medical Research InstituteCollaborator
Sheba Medical CenterCollaborator
Merck Sharp & Dohme LLCCollaborator

Investigators

1
Raz Gross, M.D., MPHPrincipal Investigator

Sites

1 total
Ramat Gan, Israel

Facts & assertions

4 sourced
Enrollment
15
Phase
NA
Primary Completion Date
2011-08
Status
TERMINATED
relationships
The graph out of here
drug
Simvastatin
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Stanley Medical Research Institute
company
Sheba Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Raz Gross, M.D., MPH
person